For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| License revenue | - | 0 | ||
| Research and development | 25,190,000 | 28,108,000 | ||
| General and administrative | 7,775,000 | 8,366,000 | ||
| Total operating expenses | 32,965,000 | 36,474,000 | ||
| (loss) income from operations | -32,965,000 | -36,474,000 | ||
| Interest and other income, net | 2,878,000 | 2,795,000 | ||
| (loss) income before income tax benefit (expense) | -30,087,000 | -33,679,000 | ||
| Income tax expense | - | 0 | ||
| Net income (loss) and comprehensive income (loss) | -30,087,000 | -33,679,000 | ||
| Earnings per share, basic | -0.66 | -0.77 | ||
| Earnings per share, diluted | -0.66 | -0.77 | ||
| Weighted average number of shares outstanding, basic | 45,779,577 | 43,797,421 | ||
| Weighted average number of shares outstanding, diluted | 45,779,577 | 43,797,421 | ||
Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE)